Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

Delayed Quote. Delayed  - 10/21 02:47:10 pm
4965 GBp   -0.25%
10/19 ASTRAZENECA : *bernstein raises astrazeneca price target to 5333 pen..
10/18DJASTRAZENECA : FDA to Review Hyperkalaemia Drug
10/18 ASTRAZENECA : Says US Regulator Accepts Hyperkalaemia Drug Re-Submis..
News SummaryMost relevantAll newsSector news 

AstraZeneca CEO Leaving As Profits Slide, Warns On Outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
04/26/2012 | 08:56am CEST

AstraZeneca PLC (AZN) Thursday said Chief Executive David Brennan is leaving after the troubled drug maker missed its first-quarter earnings and sales forecasts and cut its full-year profit targets yet again.

AstraZeneca, which reports in dollars, said net profit in the first three months of 2012 fell 44% to $1.64 billion from $2.91 billion a year earlier, missing analysts' expectations of $2.0 billion. Revenue was down 11% at $7.35 billion, compared with $8.29 billion a year earlier, worse than the $7.98 billion expected in a survey of 10 analysts.

Brennan, who used the update to announce his retirement, said, "The anticipated impact from the loss of exclusivity on several brands, together with challenging market conditions, has made for a difficult start to the year in revenue terms.

"Delivery on our restructuring plans and continued discipline on operating costs, together with the benefits from a lower tax rate, will only partially mitigate the revenue pressures. As a result we have lowered our core EPS [earnings per share] target for the full year to the range of $5.85 to $6.15."

The company previously foresaw core EPS coming in this year at $6.00 to $6.30, after $7.28 in 2011.

Brennan, an American, has been CEO since the start of 2006. Chief Financial Officer Simon Lowth will act as interim chief executive from June until a permanent successor is in place.

AstraZeneca faces crucial patent expiries between now and 2015 on products such as antipsychotic Seroquel and ulcer medicine Nexium, and the loss of patent protection in the U.S. in 2016 for its best-selling drug, heart drug Crestor. Coupled with a thinner late-stage pipeline and a mixed longer-term research and development track record, the U.K.'s No. 2 drug maker by sales has taken an aggressive approach to costs, shrinking operations and cutting thousands of jobs, while keeping cash flowing to shareholders.

In February, AstraZeneca announced it was cutting around 7,300 jobs as part of the company's ongoing cost-savings program. The first phase, launched in 2007, was aimed at improving long-term competitiveness and productivity. The second phase, announced in January 2010, envisioned the loss of up to 10,400 jobs by 2014.

Describing its outlook for 2012, the company said in a statement that "we now expect the decline in revenue for the full year will be in the range of the low to mid-teens in constant-currency terms."

AstraZeneca, which spent $5.6 billion last year buying back its own shares, Thursday said it spent $912 million in the first quarter on net stock repurchases.

AstraZeneca shares ended Wednesday at 2841 pence, down 6% on year-earlier levels.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA PLC
10/19 ASTRAZENECA : *bernstein raises astrazeneca price target to 5333 pence - 'market..
10/18DJASTRAZENECA : FDA to Review Hyperkalaemia Drug
10/18 ASTRAZENECA : Says US Regulator Accepts Hyperkalaemia Drug Re-Submission
10/18 ASTRAZENECA : Fda accepts for review new drug application for sodium zirconium c..
10/17 ASTRAZENECA PLC (NYSE : AZN) Sends Synairgen Plummeting On Ditching Asthma Drug ..
10/17 INSMED INCORPORATED : Reaches Agreement with AstraZeneca for Potential Bronchiec..
10/14 ASTRAZENECA PLC (NYSE : AZN) Offloads Two Diabetes Drugs to Focus on Core Therap..
10/13 ASTRAZENECA : *jefferies raises astrazeneca price target to 6000 pence - 'buy'
10/12 ASTRAZENECA : Faslodex Demonstrates Progression-Free Survival Advantage in 1st L..
10/12 EXTRA : AstraZeneca Stops Study Into Synairgen's Asthma Treatment
More news
Sector news : Pharmaceuticals - NEC
10/20DJE.ON to Invest $500 Million in Illinois Wind Farm
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake --..
10/19DJAbbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJPFIZER : J&J Brushes Off Pfizer's Challenge -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/18 Valeant - Salix Deal May Not Be Enough To Restore Valeant Pharmaceuticals' Pr..
10/18 FDA accepts AstraZeneca's resubmitted marketing application for hyperkalemia ..
10/17 Peregrine Pharmaceuticals - A Misunderstood And Undervalued Biotech With Sign..
10/17 Who Heard About This Biotech?
10/16 WEEK IN REVIEW : China Resources Pharma To Price $2 Billion Hong Kong IPO This W..
Financials ($)
Sales 2016 23 293 M
EBIT 2016 5 557 M
Net income 2016 2 421 M
Debt 2016 11 668 M
Yield 2016 4,61%
P/E ratio 2016 31,23
P/E ratio 2017 28,28
EV / Sales 2016 3,82x
EV / Sales 2017 3,98x
Capitalization 77 329 M
More Financials
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 69,3 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON11.83%314 270
ROCHE HOLDING LTD.-15.41%202 648
NOVARTIS AG-13.71%199 797
PFIZER INC.0.81%197 376
MERCK & CO., INC.17.23%171 222
More Results